a study of the efficacy of troxerutin in preventing thrombotic events in covid-19 patients

Conditions: COVID 19 Associated Coagulopathy

Summary: the goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe covid-19 patients. it will also learn about the safety of troxerutin. the main questions it aims to answer are: * does troxerutin lower the number of thrombotic events in participants? * what medical problems do participants have when taking troxerutin? researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in covid-19 patients. participants will: * take troxerutin or a placebo every day for 7 days. * visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests * keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type ii hit-related thrombocytopenia


Eligibility criteria:
inclusion criteria: as long as the patient meets all of the following conditions, adult patients aged 18 and above are eligible for admission: ► covid-19 patients, defined as: positive rt-pcr (upper respiratory tract or lower respiratory tract) for sars-cov-2. mild covid-19 patients are defined as: symptomatic patients meeting the case definition for covid-19 without evidence of hypoxia or pneumonia. common symptoms include fever, cough, fatigue, anorexia, dyspnea, and myalgia. other nonspecific symptoms include sore throat, nasal congestion, headache, diarrhea, nausea/vomiting, and loss of smell/taste. severe covid-19 patients are defined as: adolescents or adults with clinical signs of pneumonia (i.e., fever, cough, dyspnea, tachypnea) plus one of the following: 1. respiratory rate ≥30 breaths/min 2. severe respiratory distress 3. oxygen saturation (spo₂) ≤90% in room air 4. progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (\>50%) within 24 to 48 hours. * written informed consent provided according to chinese law (by the patient, legal guardian, or deferred consent in emergencies). exclusion criteria: patients with any of the following conditions will be excluded from the study: * pregnant or lactating women. * postpartum (within 6 weeks). * extreme weight (100 kilograms). * clinical need for heparin therapy. * bleeding related to coagulation disorders, acute clinically significant bleeding, active gastrointestinal ulcers, or any organic lesions with high bleeding risk. * platelet count \<50 x 10\^9/l. * surgery within the last 15 days, or within 24 hours after spinal or epidural anesthesia. * history of intracranial hemorrhage, large ischemic stroke, known intracranial malformation or tumor, acute infective endocarditis. * severe renal impairment (creatinine clearance \<30 ml/min). * iodine allergy. * long-term use of oxygen supplementation. * moribund patients or those expected to die during the current hospitalization due to underlying disease. * patients deprived of freedom and those undergoing institutional psychiatric care. * ward of the state or under guardianship. * participation in other anticoagulant intervention studies.